{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:26:16Z","timestamp":1782444376687,"version":"3.54.5"},"reference-count":15,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.breast.2014.08.015","type":"journal-article","created":{"date-parts":[[2014,9,25]],"date-time":"2014-09-25T22:51:09Z","timestamp":1411685469000},"page":"816-820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer"],"prefix":"10.1016","volume":"23","author":[{"given":"Victor","family":"Pernin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Belin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cottu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Bontemps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Lemanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"De La Lande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernand","family":"Missohou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Peignaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Bougnoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bollet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Dendale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora Ady","family":"Vago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Fourquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youlia M.","family":"Kirova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.breast.2014.08.015_bib1","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1158\/0008-5472.CAN-06-3664","article-title":"Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors","volume":"67","author":"Kozin","year":"2007","journal-title":"Cancer Res"},{"issue":"5706","key":"10.1016\/j.breast.2014.08.015_bib2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.breast.2014.08.015_bib3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(12)70049-9","article-title":"Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study","volume":"13","author":"Pierga","year":"2012","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.breast.2014.08.015_bib4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0360-3016(79)90729-6","article-title":"Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast","volume":"5","author":"Harris","year":"1979","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.breast.2014.08.015_bib5","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijrobp.2009.11.021","article-title":"Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with bevacizumab","volume":"79","author":"Goyal","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.breast.2014.08.015_bib6","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2005.03.6780","article-title":"Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer","volume":"24","author":"Crane","year":"2006","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.breast.2014.08.015_bib7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1748-717X-6-105","article-title":"Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study","volume":"6","author":"Velenik","year":"2011","journal-title":"Radiat Oncol Lond Engl"},{"issue":"18","key":"10.1016\/j.breast.2014.08.015_bib8","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1200\/JCO.2008.21.1771","article-title":"Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study","volume":"27","author":"Willett","year":"2009","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2014.08.015_bib9","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ijrobp.2010.02.037","article-title":"Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HypoArc) for rectal cancer: a phase II study","volume":"80","author":"Koukourakis","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.breast.2014.08.015_bib10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijrobp.2010.08.005","article-title":"Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer","volume":"82","author":"Dipetrillo","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.breast.2014.08.015_bib11","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1634\/theoncologist.2010-0285","article-title":"Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study","volume":"16","author":"Nogu\u00e9","year":"2011","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.breast.2014.08.015_bib12","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ijrobp.2010.07.024","article-title":"Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas","volume":"81","author":"Yoon","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.breast.2014.08.015_bib13","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"20","key":"10.1016\/j.breast.2014.08.015_bib14","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"26","key":"10.1016\/j.breast.2014.08.015_bib15","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N\u00a0Engl J Med"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977614001647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977614001647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:33:17Z","timestamp":1760776397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977614001647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0960977614001647"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2014.08.015","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2014.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}